NSE: GRANULES · 29 October 2026
- Granules India Ltd. (GRANULES) declined by 0.37% to close at ₹837.35 on Wednesday, moving within an intraday range of ₹823.35 to ₹842.85 from an opening level of ₹834.00.
- Granules India Limited announced the incorporation of a wholly owned foreign subsidiary named Triton Farmaceutica S.A. de C.V. in Mexico. The newly formed entity is established to manufacture, promote, sell, and distribute pharmaceutical products in the Mexican market and has not yet commenced business operations. The subsidiary was incorporated with authorized shares of 450,000 valued at MXN 10.00 each.
- Trading volume was 0.70 times the 20-day average daily volume.
Why is Granules India share price falling on 29 October 2026?
Granules India Ltd. (GRANULES) declined by 0.37% to close at ₹837.35 on Wednesday, moving within an intraday range of ₹823.35 to ₹842.85 from an opening level of ₹834.00.
While the broader equity market showed positive momentum with the Nifty rising 1.05% and the Nifty Pharma sector benchmark gaining 0.64%, Granules India underperformed its sector peers slightly. The stock's modest pullback follows a positive 5-day return of 2.49%, though it remains down 3.39% over a 20-day horizon, reflecting ongoing consolidation near its 52-week high of ₹923.65 and low of ₹529.85.
The session move occurred in the absence of any fresh same-day catalysts, serving instead as routine consolidation after recent gains. Recent corporate updates show the company expanding its international footprint by incorporating a wholly owned foreign subsidiary, Triton Farmaceutica S.A. de C.V., in Mexico on October 22, 2026, following a similar subsidiary formation in Brazil earlier in October. Additionally, the company previously announced securing potential first-to-file status for Ruxolitinib Extended-Release Tablets ANDA in October, though these developments provided background context rather than direct downward catalysts for today's minor price adjustment.
5.05 lakh shares traded by 29 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 7.18 lakh shares (0.70 times). The five-day average daily volume was 6.21 lakh shares. Separately, the NSE report for 28 October 2026 showed 1.13 lakh shares delivered, representing 48.99% of that day’s traded volume. The same report recorded 15,673 trades.
Granules India shares drifted lower by 0.37% with below-average volume participation, reflecting minor profit-taking and consolidation after a 5-day return of 2.49%. No single confirmed fundamental trigger was identified for today's price action.
Latest Company Developments
Granules India Limited announced the incorporation of a wholly owned foreign subsidiary named Triton Farmaceutica S.A. de C.V. in Mexico. The newly formed entity is established to manufacture, promote, sell, and distribute pharmaceutical products in the Mexican market and has not yet commenced business operations. The subsidiary was incorporated with authorized shares of 450,000 valued at MXN 10.00 each.
This expansion reinforces the company's long-term international distribution strategy across regulated and emerging pharmaceutical markets.
The company announced the submission of a Paragraph IV certification for its ANDA for Ruxolitinib Extended-Release Tablets. Based on the timing and status of the filing, Granules India believes it is eligible for first-to-file status, which could potentially grant 180 days of generic drug exclusivity under U.S. law upon final FDA review and approval.
Successful confirmation of first-to-file status creates high-value commercial opportunities in the U.S. generic drug market.
Granules India reported the incorporation of another wholly owned foreign subsidiary, Triton Farmaceutica do Brasil Ltda, in Brazil. The unit aims to manufacture, promote, and distribute pharmaceuticals locally and received prior approval from the Reserve Bank of India under the automatic route.
It broadens the company's direct operational footprint in Latin America to support future commercial growth.
Granules India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
a press release dated Jun 03, 2026, titled "Granules Pharmaceuticals, Inc. Receives USFDA EIR for Chantilly Facility".
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 4.26% on 30 September 2026. This compares with 4.18% on 16 September 2026, a change of +0.08 percentage points.
The filing reported 27 MF/UTI holders.
Research & Brokerage Views
Analyst Ruchit Jain suggested Granules India shares as a short-term buy based on technical setup and market momentum.
Historical Bulk / Block Deals
What to Watch Next
- Upcoming financial results for the second quarter and half-year ended September 30, 2026, scheduled for November 2, 2026.
- Progress on U.S. FDA regulatory reviews for Ruxolitinib Extended-Release Tablets ANDA filing.
- Operational developments and business rollout for newly incorporated subsidiaries in Mexico and Brazil.
- Delivery volume trends against the 20-day average volume of 721,000 shares.
More Granules India news and dated analysis →
Frequently Asked Questions
What is the latest Granules India company news?
Granules India Limited announced the incorporation of a wholly owned foreign subsidiary named Triton Farmaceutica S.A. de C.V. in Mexico. The newly formed entity is established to manufacture, promote, sell, and distribute pharmaceutical products in the Mexican market and has not yet commenced business operations. The subsidiary was incorporated with authorized shares of 450,000 valued at MXN 10.00 each.
How strong was Granules India’s trading volume?
5.05 lakh shares traded, 0.70 times the 20-day average daily volume. The price and volume data are dated 29 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.